Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Summit Therapeutics Inc. - Common Stock (NQ: SMMT )

18.10 -0.07 (-0.39%)
Streaming Delayed Price Updated: 10:21 AM EST, Jan 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 429,593
Open 18.48
Bid (Size) 18.04 (6)
Ask (Size) 18.10 (5)
Prev. Close 18.17
Today's Range 17.66 - 18.57
52wk Range 2.100 - 33.89
Shares Outstanding 97,381,774
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioNTech Positioned For Solid Growth Amid Oncology Transition: Analyst
Truist rates BioNTech a Buy, citing its shift to oncology with BNT327 leading the way. Key data updates and growth catalysts are expected by 2025. 
Via Benzinga
This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga

Performance

YTD
-1.36%
-1.36%
1 Month
-3.10%
-3.10%
3 Month
-10.62%
-10.62%
6 Month
+91.13%
+91.13%
1 Year
+423.12%
+423.12%

More News

Read More
Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside
Via Benzinga
Summit Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Summit Therapeutics Inc.
Via Business Wire
Where Will Summit Therapeutics Be in 5 Years?
Via The Motley Fool
How Is The Market Feeling About Summit Therapeutics?
Via Benzinga
Prediction: These 3 Healthcare Stocks Will Soar in 2025
Via The Motley Fool
3 Stocks That Could Be Monster Winners in 2025
Via The Motley Fool
3 Stocks That Could Turn $1,000 into $5,000 by 2030
Via The Motley Fool
3 No-Brainer Biotech Stocks to Buy With $200 Right Now
Via The Motley Fool
2 Soaring Stocks That Could Climb 68% to 166% Higher in 2025, According to Wall Street
Via The Motley Fool
Investing $5,000 in Each of These 3 Stocks at the Start of 2024 Would Have Created a Portfolio Worth More Than $100,000 Today
Via The Motley Fool
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics Inc.
Via Business Wire
Why Summit Therapeutics Stock Rocketed 6% Higher on Friday
Via The Motley Fool
Billionaire Ken Griffin Is Selling Palantir and Buying a Stock Wall Street Expects to Rocket 139% Higher
Via The Motley Fool
Warning: This Skyrocketing Stock Has a Hidden Risk
Via The Motley Fool
Summit Therapeutics to Present at Upcoming Investor Conferences
From Summit Therapeutics Inc.
Via Business Wire
3 Monster Stocks in the Making
Via The Motley Fool
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics Inc.
Via Business Wire
Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics
Via Investor's Business Daily
BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential
Via Benzinga
MarketBeat Week in Review – 11/4 - 11/8
Via MarketBeat
Topics Economy Government
Exposures Interest Rates Political
2 Hot Biopharma Stocks to Buy and Hold for 5 Years
Via The Motley Fool
Why Summit Therapeutics Stock Was a Winner Today
Via The Motley Fool
Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.